Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06940518
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Clear Cell Renal Carcinoma
- Ivonescimab
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ivonescimab — DRUGGiven by IV
Study Details
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
Key Dates
- Start date
- Jul 2, 2025
- Status verified
- May 2026
- Primary completion
- Jan 19, 2028
- Completion
- Jan 19, 2030
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 2 - (Post-ICB/VEGFTKI)Treatment with Ivonescimab IV Q3W
- Experimental: Cohort 1 - (Post-pure-ICB)Treatment with Ivonescimab IV Q3W
Primary Outcome Measure
Safety and adverse events [ Time Frame: Through study completion; an average of 1 year. ]
Central Contacts
- Pavlos Msaouel, MD713-563-4585
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | Pavlos Msaouel, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesPHASE2 · Not Yet Recruiting · Kelly Fitzgerald, MD · San Francisco, California